GNGBY: AI 评分 47/100 — AI 分析 (4月 2026)

Getinge AB (publ) is a Swedish company providing equipment and solutions for healthcare facilities globally. The company operates through three segments: Acute Care Therapies, Life Science, and Surgical Workflows.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.

GNGBY是做什么的？

Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.

GNGBY的投资论点是什么？

Getinge AB (publ) presents a notable market position due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.79 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.

GNGBY在哪个行业运营？

Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.

Medical Devices

Healthcare

GNGBY有哪些增长机遇？

Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.

Market capitalization of $5.43 billion reflects Getinge's significant presence in the medical device industry.
Profit margin of 6.5% indicates efficient operations and profitability.
Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
Dividend yield of 2.43% provides an income stream for investors.
Beta of 0.88 suggests lower volatility compared to the overall market.

GNGBY提供哪些产品和服务？

Provides equipment for operating rooms and intensive-care units.
Offers sterilization solutions for healthcare facilities.
Develops and manufactures bioprocessing systems for the life science industry.
Provides surgical workflows solutions.
Offers acute care therapies, including anesthesia and ventilation equipment.
Provides sterile transfer systems and closure processing systems.

GNGBY如何赚钱？

Sells medical devices and equipment to hospitals, clinics, and research institutions.
Provides service and maintenance contracts for its equipment.
Offers software solutions for managing surgical workflows and bioprocessing operations.
Generates revenue through a network of proprietary sales companies, agents, and distributors.

Hospitals and clinics
Research institutions
Pharmaceutical and biotechnology companies
Sterilization departments

Established brand reputation and long-standing relationships with customers.
Extensive distribution network and global reach.
Diversified product portfolio across multiple healthcare segments.
Strong focus on innovation and research and development.

什么因素可能推动GNGBY股价上涨？

Ongoing: Increasing demand for healthcare solutions driven by an aging global population.
Ongoing: Advancements in medical technology and innovation.
Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
Ongoing: Expansion in emerging markets with developing healthcare infrastructure.
Ongoing: Development of integrated solutions combining hardware, software, and services.

GNGBY的主要风险是什么？

Potential: Currency fluctuations impacting revenue and profitability.
Potential: Changes in healthcare regulations and reimbursement policies.
Ongoing: Competition from other medical device manufacturers.
Potential: Product recalls or safety concerns.
Potential: Economic downturns affecting healthcare spending.

GNGBY的核心优势是什么？

Diversified product portfolio
Global presence and distribution network
Strong brand reputation
Focus on innovation

GNGBY的劣势是什么？

Exposure to currency fluctuations
Dependence on healthcare spending
Competition from larger medical device companies
Potential for product recalls

GNGBY有哪些机遇？

Expansion in emerging markets
Development of integrated solutions
Strategic acquisitions
Increasing demand for bioprocessing solutions

GNGBY面临哪些威胁？

Changes in healthcare regulations
Economic downturns
Technological obsolescence
Increased competition

GNGBY的竞争对手是谁？

Abbott Laboratories — Diversified healthcare company with a broad range of products. — (ABT)
Align Technology — Focuses on orthodontic products and solutions. — (ALGN)
Bio-Rad Laboratories — Develops and manufactures products for the life science research and clinical diagnostics markets. — (BIO)
Bruker Corporation — Provides scientific instruments and solutions for life science, materials research, and diagnostics. — (BRKR)
CONMED Corporation — Surgical and patient monitoring products and services. — (CNMD)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Mattias Perjos
Headquarters: Gothenburg, SE
Employees: 11,827
Founded: 2012

AI Insight

AI analysis pending for GNGBY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: GNGB

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Getinge AB (publ) do?

Getinge AB (publ) provides a wide array of medical technology solutions, focusing on equipment and systems for operating rooms, intensive care units, and sterilization departments. The company operates through three segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its products range from anesthesia machines and ventilators to bioprocessing equipment and surgical tables, serving hospitals, research institutions, and pharmaceutical companies globally. Getinge aims to improve patient outcomes and optimize healthcare processes through its innovative solutions.

What do analysts say about GNGBY stock?

Analyst consensus on GNGBY stock is pending, as AI analysis is not yet available. Investors should monitor analyst ratings and price targets for updates. Key valuation metrics to consider include the company's P/E ratio, dividend yield, and growth prospects. Factors influencing analyst opinions include Getinge's financial performance, market position, and industry trends. It is important to conduct independent research and consider multiple perspectives before making investment decisions.

What are the main risks for GNGBY?

GNGBY faces several risks, including currency fluctuations due to its global operations, which can impact revenue and profitability. Changes in healthcare regulations and reimbursement policies could also affect the demand for its products. Intense competition from other medical device manufacturers poses a threat to market share. Additionally, product recalls or safety concerns could damage the company's reputation and financial performance. Economic downturns may reduce healthcare spending, impacting Getinge's sales.